Piper Jaffray upgraded Catalyst Pharma (NASDAQ:CPRX) from Neutral to Overweight in a statement released earlier today.
- Updated: October 5, 2016
Piper Jaffray has upgraded Catalyst Pharma (NASDAQ:CPRX) from Neutral to Overweight in a statement released on Wednesday October 05, 2016.
Displaying a price of $1.12, Catalyst Pharma (NASDAQ:CPRX) traded 28.57% higher on the day. The last stock price close is up 64.33% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. CPRX has recorded a 50-day average of $1.04 and a two hundred day average of $0.88. 3,046,347 shares of the stock were exchanged, up from an average trading volume of 770,974
See Chart Below
Catalyst Pharma has a 52 week low of $0.51 and a 52 week high of $3.55 Catalyst Pharma’s market capitalization is presently $0.
A total of 4 brokers have issued a report on the company. zero equity analysts rating the stock a strong buy, 4 analysts rating the company a buy, 0 brokers rating the stock a hold, zero brokerages rating the company a underperform, and finally 0 equity analysts rating the company a sell with a one year target of $6.81.
More About Catalyst Pharma (NASDAQ:CPRX)
Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.